Photo by adigold1 from unsplash
Since the publication of the first two novel reports demonstrating the feasibility of using Hepatitis C virus nucleic acid test positive (HCV NAT+) organs into negative recipients1,2 , evidence regarding… Click to show full abstract
Since the publication of the first two novel reports demonstrating the feasibility of using Hepatitis C virus nucleic acid test positive (HCV NAT+) organs into negative recipients1,2 , evidence regarding the safety of using HCV NAT+ organs have been mounting. However, the wide implementation of such a practice hinges on the ability to ensure timely delivery of direct acting antiviral (DAA) therapy after transplantation. To date, DAA coverage by third party payers for acute HCV infection cannot be guaranteed.
Keywords:
use hcv;
party payers;
expanding use;
third party
Journal Title: American Journal of Transplantation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: American Journal of Transplantation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!